One of only three CIADMs to be developed in the U.S., the Texas A&M Center is at the vanguard of U.S. pandemic-preparedness efforts and represents unprecedented public-health collaboration among state and federal governments, academia and private industry. Once constructed and operational, the Center's influenza manufacturing facility will be able to supply 50 million doses of pandemic influenza vaccine within four months of an outbreak. BARDA conceived the public-private formula to assure a strong biosecurity product development and manufacturing base on U.S. soil, ensuring that the nation would have rapid access to vaccines and therapeutics in the advent of influenza pandemics, or chemical, biological, radiological, and nuclear attacks.
"We are honored to welcome GSK to Texas A&M as a key partner in the Center for Innovation," said Sharp. "GSK's dedication to public service is well-aligned with the Texas A&M tradition of serving the nation and defining its future through research and scholarship. Equally important is the cultural and philosophical match between GSK and the A&M System, as reflected by GSK's desire to collaborate with academia and the U.S. government, and their ongoing commitment to helping address global health scourges such as pandemic influenza and malaria."
The Texas A&M Center for Innovation is led by Dr. Brett Giroir, Vice Chancellor for Strategic Initiatives at the Texas A&M System, and a core team of A&M experts in biotechnology, infectious diseases, facilities planning and construction, federal acquisitions/contracting, and government affairs. The partnership with GSK was founded on a long, collaborative relationship between Texas A&M and the Wallonia Region of Belgium, with specific planning for this project beginning in the spring of 2010.
"GSK's decision to partner with Texas A&M and bring their vaccine manufacturing to our state is a testament to the investments that the A&M System and the State of Texas have made in the people, infrastructure and technologies, much of which came from critical state programs such as the Emerging Technology Fund," Giroir said. "GSK brings unequaled influenza vaccine development, manufacturing, and regulatory expertise to our Center. Equally important, GSK brings its cell based influenza vaccine development program, which we have assessed to be the most promising near term influenza vaccine technology to improve upon current egg based vaccines."The Texas A&M Center for Innovation represents the largest commitment of a global biopharmaceutical company to partner within Texas, and will be an important catalyst to the future growth of this industry within the State. U.S. Government FundingEfforts highlighted in this release have been funded in whole or in part with Federal Funds from the DHHS/ASPR/BARDA, under contract numbers HHSO100200600011C, HHSO100200700029C and HHSO100201200002I. About the A&M SystemThe A&M System is one of the largest systems of higher education in the nation, with a budget of $3.5 billion. Through a statewide network of 11 universities, seven state agencies and a comprehensive health science center, the A&M System educates more than 120,000 students and makes more than 22 million additional educational contacts through service and outreach programs each year. Externally funded research expenditures exceed $780 million and help drive the state's economy. Steven B. Moore Texas A&M University System 979-458-6023 Syscomm@tamus.edu About the Texas A&M Center for InnovationThe Texas A&M Center for Innovation in Advance Development and Manufacturing (CIADM) is one of three centers established in June, 2012 by the US Department of Health and Human Services to enhance the nation's emergency preparedness against emerging infectious diseases, including pandemic influenza, and chemical, biological, radiological and nuclear threats. The Center is founded on an initial $285.6 million investment, including a $176.6 million contribution from the US Department of Health and Human Services, with the remainder cost-shared by commercial and academic proposal partners. The Center will perform research and advanced development to accelerate vaccines and other medical products through pre-clinical and clinical development and produce these products in cases of pandemics or other national emergencies. Through these activities, the Center will address a recognized shortcoming in preparedness and response to known and unknown threats, and will improve our nation's ability to protect the health of its citizens in emergency situations.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV